These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20433538)

  • 1. New data on ONTARGET: more confusion?
    Escobar C; Echarri R; Barrios V
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
    [No Abstract]   [Full Text] [Related]  

  • 2. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 3. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 4. Proteinuria: Is the ONTARGET renal substudy actually off target?
    Ruggenenti P; Remuzzi G
    Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 6. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
    Nilsson PM
    Lakartidningen; 2008 May 7-13; 105(19):1382-4. PubMed ID: 18574975
    [No Abstract]   [Full Text] [Related]  

  • 7. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
    Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ONTARGET: questions asked, questions answered.
    Weber MA
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
    [No Abstract]   [Full Text] [Related]  

  • 10. ONTARGET should not be over interpreted.
    Abutaleb N
    Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
    [No Abstract]   [Full Text] [Related]  

  • 11. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
    Düsing R; Nitschmann S
    Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.
    Wang JG; Pimenta E; Chwallek F
    Vasc Health Risk Manag; 2014; 10():189-200. PubMed ID: 24741317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is therapy of people with chronic kidney disease ONTARGET?
    Mann JF; Tobe S; Teo KK; Yusuf S
    Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A; Baliga V;
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 18. A third amlodipine/ARB combination (Twynsta) for hypertension.
    Med Lett Drugs Ther; 2010 Jan; 52(1329):2-3. PubMed ID: 20208469
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan in the treatment of hypertension.
    Rosario BH; Hendra TJ
    Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):485-92. PubMed ID: 18433350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.